China fast-tracks brain-computer interfaces: world-first implant approval, then an insurance code within 48 hours

The Economist ("China wants to get inside your head", 6 October) describes how China has made brain-computer interfaces (BCIs) a national priority and names the companies leading the push: BrainCo (non-invasive wearables, founded in Hangzhou), NeuroXess (wireless implant trials), StairMed (which The Economist describes as Alibaba-backed), the state-backed NeuCyber, and Neuracle, whose implant was the first invasive BCI to win market approval anywhere.

• On 13 March 2026 China's National Medical Products Administration approved Neuracle's implantable BCI for hand motor function (NEO) under its fast-track pathway for innovative devices. Xinhua called it the world's first market approval for an invasive BCI medical device. It is meant for adults with quadriplegia from cervical spinal-cord injury and restores grasping through a pneumatic glove driven by decoded brain signals.
• Within about 48 hours, China's National Healthcare Security Administration issued billing codes for the device, and Shanghai listed it for hospital use within weeks. Shanghai's commercial supplementary insurance scheme later covered part of the consumables cost.
• The first commercial NEO implant was carried out at Shanghai's Huashan Hospital in July, and Neuracle's STAR Market IPO prospectus was accepted for review on 11 June 2026.
• China's 15th Five-Year Plan (2026-2030) lists BCI as one of six key future industries, and BCI featured in the government work report for the first time in March 2026. Shanghai says it has nurtured about 60 BCI companies, including Neuracle, NeuroXess and StairMed, and is targeting full clinical adoption by 2030.

The striking part is the speed of the state machinery: approval, a reimbursement code and hospital listing in weeks rather than years. The Economist's framing is that this is a deliberate industrial strategy rather than a one-off; how quickly these devices reach meaningful patient volumes, and at what cost, is still unproven.

BCI is moving from lab to clinic first in China. US and European implant developers and their regulators will increasingly be benchmarked against this approval-to-reimbursement timeline, and the Chinese cohort is building commercial track records and listing plans while most Western peers remain in trials.

The Economist: https://www.economist.com/business/2026/10/06/china-wants-to-get-inside-your-head
Xinhua: https://english.news.cn/20260314/fab8a8e69f004c74a6b40e2d6ae5bc54/c.html
Yicai Global: https://www.yicaiglobal.com/news/chinese-startup-neuracles-bci-system-is-first-in-world-to-be-cleared-for-clinical-use
Global Times: https://www.globaltimes.cn/page/202603/1357537.shtml
Inside BCI: https://insidebci.com/news/2026-07-16-neuracle-neo-shanghai-huashan-first-commercial-invasive-bci-motor-restoration/